爱必妥联合CDDP化疗方案治疗恶性原发性肝癌的临床疗效研究  

Clinical efficacy of erbitux combined with CDDP chemotherapy on patients with malignant primary liver cancer

作　　者：卢转飞 徐雪明 陈明聪 何桂芬[2] 

机构地区：[1]台州市肿瘤医院肿瘤放化疗科,台州317502 [2]复旦大学附属肿瘤医院肿瘤内科,上海200032

出　　处：《实用药物与临床》2014年第9期1162-1165,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的探讨爱必妥联合CDDP化疗方案治疗恶性原发性肝癌的临床疗效。方法选取2011年1月至2013年12月来我院就诊的恶性原发性肝癌患者68例,依据分层随机分组方法将患者分为治疗组与对照组,每组34例。治疗组予以静滴爱必妥,第1周初始剂量400 mg/m2,以后250 mg/m2,1次/周;联合CDDP化疗方案。对照组予以CDDP化疗方案。两组均治疗8周。观察两组患者治疗前及治疗8周后肝功能,以及治疗后的总缓解率(RR)及临床受益率(CBR),同时比较两组患者治疗前及治疗2、4、6、8周后的血清甲胎蛋白(AFP)。结果治疗前两组患者指标无明显差异(P>0.05),治疗8周后,治疗组患者总有效率(61.76%)及临床受益率(85.29%)均明显高于对照组的35.29%及61.76%(P<0.05),而治疗组治疗2、4、6、8周后的血清甲胎蛋白明显低于对照组;同时,治疗8周后,治疗组患者的肝功能明显优于对照组(P<0.05)。两组患者均无皮肤过敏症状及消化道不适等不良反应。结论相比于仅采用CDDP化疗方案来治疗恶性原发性肝癌,应用爱必妥联合CDDP化疗方案能更好地缓解患者的病情,改善中晚期患者的肝功能,提高治疗的总体效果,值得临床推广使用。Objective To explore the clinical efficacy of erbitux combined with CDDP chemotherapy on patients with malignant primary liver cancer.Methods 68 patients with malignant primary liver cancer who came to our hospital from January 2011 to December 2013 were selected.The patients were divided into treatment group and control group according to stratified randomization method,34 cases in each group.Treatment group was ivgtt administered with erbitux,the initial dose was 400 mg/m2 in the first week and 250 mg/m2 afterwards,once weekly,combined with CDDP chemotherapy.Control group was given CDDP chemotherapy.Both groups were treated for 8 weeks.The hepatic function,overall response rate（RR） and clinical benefit rate（CBR） before and 2 weeks after treatment of the two groups were compared.The serum AFP before and 2,4,6,8 weeks after the treatment were compared.Results The difference of indexes was not significant before treatment between the 2 groups （P ＞ 0.05） ;After 8 weeks of the treatment,the o verall response rate and clinical benefit rate of treatment group（61.76％,85.29％）were significantly higher than those of control group（35.29％,61.76％）.The AFP of treatment group was much lower than that of control group after 2,4,6,8 weeks of treatment.Meanwhile,the hepatic function of treatment group was significantly higher than that of control group after 8 weeks of treatment（P ＜ 0.05）.There were no skin allergies,gastrointestinal discomfort and other adverse reactions of the two groups.Conclusion Compared with the conventional CDDP chemotherapy,erbitux combined with CDDP chemotherapy is better at alleviating the patient＇s condition,improving patients＇ hepatic function and the overall effectiveness of treatment,It is worthy of clinical application.

关 键 词：爱必妥 CDDP化疗方案 恶性原发性肝癌 甲胎蛋白 缓解率 

分 类 号：R735.7[医药卫生—肿瘤]